We could not find any results for:
Make sure your spelling is correct or try broadening your search.
REDWOOD CITY, CA -- (Marketwire) -- 04/05/10 -- Facet Biotech Corporation (NASDAQ: FACT) today announced that data for the company's daclizumab development program will be presented at the...
PDL BioPharma Clarifies $13.00 Cost Basis in Facet Biotech Corporation PR Newswire INCLINE VILLAGE, Nev., March 24 INCLINE VILLAGE, Nev., March 24 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc...
Bull & Lifshitz, LLP announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of Facet Biotech Corporation (NASDAQ: FACT...
Kendall Law Group, a national securities litigation firm is investigating Facet Biotech Corporation (NASDAQ: FACT) for shareholders in connection to the proposed sale of the...
Law Offices of Howard G. Smith announces that it is investigating potential claims against the board of directors of Facet Biotech Corporation (“Facet Biotech” or the “Company”...
Levi & Korsinsky is investigating the Board of Directors of Facet Biotech Corporation (“Facet Biotech” or the “Company”) (NasdaqGM: FACT) for possible breaches of fiduciary duty...
(Adds comment from Biogen Idec) DOW JONES NEWSWIRES Abbott Laboratories (ABT) will bulk up its product pipeline with a $722 million deal that will finally send Facet Biotech Corp. (FACT) walking...
Abbott Laboratories (ABT) will bulk up its product pipeline with a $722 million deal that will finally send Facet Biotech Corp. (FACT) walking down the aisle after it rebuffed development partner...
ABBOTT PARK, Ill. and REDWOOD CITY, Calif., March 9 /PRNewswire-FirstCall/ -- Abbott and Facet Biotech Corporation announced today a definitive agreement for Abbott to acquire Facet, enhancing...
REDWOOD CITY, CA -- (Marketwire) -- 02/23/10 -- Facet Biotech Corporation (NASDAQ: FACT) today reported financial results for the fourth quarter and full year ended December 31, 2009. "In our...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions